Moderna, Inc. Common Stock vs. Repligen Corp
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| MRNA | RGEN | |
|---|---|---|
| Market Cap | $25.14 billion | $9.95 billion |
| Revenue (TTM) | $2.23 billion | $785.10 million |
| Net Income (TTM) | $-3,151,000,000 | $41.54 million |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| MRNA | RGEN | |
|---|---|---|
| P/E Ratio | — | 241.59 |
| Price / Book | 3.72 | 4.71 |
| Price / Sales | 11.28 | 12.68 |
MRNA leads on 2 of 2 valuation factors.
Profitability
| MRNA | RGEN | |
|---|---|---|
| Net Margin | -141.43% | 5.29% |
| Return on Equity | -46.61% | 1.97% |
RGEN leads on 2 of 2 profitability factors.
Risk & Sentiment
| MRNA | RGEN | |
|---|---|---|
| Short Interest | 0.01% | 7.13% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: MRNA overview, MRNA financials, RGEN overview, RGEN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.